Caroline Mann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline Mann has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Petra Staubach
Hautklinik und Poliklinik Universitätsmedizin Mainz
10 shared publications- Gregor Ojak
Department of Dermatology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
4 shared publications Stephan Grabbe
Hautklinik und Poliklinik Universitätsmedizin Mainz
4 shared publications- Berenice Mareen Lang
Department of Dermatology, University Medical Center Mainz, Mainz 55131, Germany
3 shared publications - Alexander Thiem
Clinic and Policlinic for Dermatology and Venereology University Medical Center Rostock Rostock Germany
2 shared publications - Alexandra Strobel
Institute of Medical Epidemiology, Biostatistics, and Informatics, Interdisciplinary Center for Health Sciences, Medical Faculty of Martin Luther University Halle-Wittenberg, Wittenberg, Germany
2 shared publications
Latest Publications
- 8 October 2026
- Published by Springer Nature in Somnologie
- Vol. 30 (S2) , 11-12
Schlaf – Wirtschafts- und Karrierefaktor
- 8 October 2026
- Published by Springer Nature in Somnologie
- Vol. 30 (S2) , 11-12
Schlaf – Wirtschafts- und Karrierefaktor
- Open Access
- 30 July 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Patient treatment needs in atopic dermatitis: A real‐world cohort study
Background: Atopic dermatitis (AD) substantially affects quality of life, yet standardized severity measures may not capture patient‐centred priorities, making systematic needs assessment essential for personalized care. Objectives: This study aimed to systematically assess and rank treatment needs in adults with moderate to severe AD, identify patient subgroups with distinct need profiles and evaluate how well these needs were met after 2 years of specialized dermatological care. Methods: In this prospective observational study from the TREATgermany registry, 697 adults with moderate to severe AD completed the validated Patient Benefit Index (PBI) at baseline (T1) and at 2‐year follow‐up (T2), capturing treatment goal importance and achievement. Subgroup analyses were performed based on age, sex, educational status and age at AD onset. Associations between clinical measures and perceived benefit were analysed. Results: The most frequently prioritized treatment goals were being free of itching (97.8% high agreement), regaining control of the disease (95.3%) and relief from skin burning (92.0%). The importance of itch reduction was not correlated with baseline pruritus intensity, and perceived benefit was more closely linked to relative clinical improvement than to absolute disease severity. Beyond these shared priorities, treatment needs varied across subgroups: older patients valued treatment safety and reduced dependence on medical care, women emphasized psychosocial and appearance‐related goals, individuals with lower educational status highlighted financial concerns and patients with adult‐onset AD prioritized diagnostic certainty and disease control. After 2 years, 96.6% of patients reported meaningful treatment benefit. Patient‐reported outcomes (POEM) were more strongly associated with perceived benefit than physician‐assessed measures (oSCORAD, EASI). Conclusion: Patient treatment needs in AD vary by demographic and clinical factors, with pruritus consistently rated as the highest priority. Patient‐reported outcomes align more closely with perceived benefit than physician assessments, underscoring the value of systematic needs assessments to guide individualized treatment decisions and shared decision‐making.
- 30 July 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Open AccessPatient treatment needs in atopic dermatitis: A real‐world cohort study
Background: Atopic dermatitis (AD) substantially affects quality of life, yet standardized severity measures may not capture patient‐centred priorities, making systematic needs assessment essential for personalized care. Objectives: This study aimed to systematically assess and rank treatment needs in adults with moderate to severe AD, identify patient subgroups with distinct need profiles and evaluate how well these needs were met after 2 years of specialized dermatological care. Methods: In this prospective observational study from the TREATgermany registry, 697 adults with moderate to severe AD completed the validated Patient Benefit Index (PBI) at baseline (T1) and at 2‐year follow‐up (T2), capturing treatment goal importance and achievement. Subgroup analyses were performed based on age, sex, educational status and age at AD onset. Associations between clinical measures and perceived benefit were analysed. Results: The most frequently prioritized treatment goals were being free of itching (97.8% high agreement), regaining control of the disease (95.3%) and relief from skin burning (92.0%). The importance of itch reduction was not correlated with baseline pruritus intensity, and perceived benefit was more closely linked to relative clinical improvement than to absolute disease severity. Beyond these shared priorities, treatment needs varied across subgroups: older patients valued treatment safety and reduced dependence on medical care, women emphasized psychosocial and appearance‐related goals, individuals with lower educational status highlighted financial concerns and patients with adult‐onset AD prioritized diagnostic certainty and disease control. After 2 years, 96.6% of patients reported meaningful treatment benefit. Patient‐reported outcomes (POEM) were more strongly associated with perceived benefit than physician‐assessed measures (oSCORAD, EASI). Conclusion: Patient treatment needs in AD vary by demographic and clinical factors, with pruritus consistently rated as the highest priority. Patient‐reported outcomes align more closely with perceived benefit than physician assessments, underscoring the value of systematic needs assessments to guide individualized treatment decisions and shared decision‐making.
- Open Access
- 7 July 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 896-904
Langanhaltende Krankheitskontrolle der disseminierten superfiziellen aktinischen Porokeratose (DSAP) mittels topischer Anwendung von 2% Simvastatin/2% Cholesterin‐Creme
Zusammenfassung: Einleitung: Die disseminierte superfizielle aktinische Porokeratose (DSAP) ist eine seltene Keratinisierungsstörung, die mit einem erhöhten Risiko für kutane Tumoren verbunden ist. Zielsetzung: Ziel der Studie war die Entwicklung eines praktikablen und einfach anwendbaren Behandlungsregimes für die langfristige Kontrolle der DSAP einschließlich der Prävention neuer Hauttumoren. Patienten und Methodik: Insgesamt 19 Patienten mit DSAP wurden über einen Zeitraum von maximal 18 Monaten topisch mit einer Creme mit 2% Simvastatin und 2% Cholesterin (SC) behandelt. Der Schweregrad der Erkrankung wurde mittels Investigator Global Assessment (IGA) bewertet, während die Lebensqualität mittels Dermatology Life Quality Index (DLQI) erfasst wurde. Nebenwirkungen sowie die Entwicklung neuer Tumoren wurden dokumentiert. Ergebnisse: In allen behandelten Bereichen zeigte sich eine signifikante Verbesserung der IGA‐Werte (p < 0,001), wobei die meisten Fortschritte innerhalb der ersten 3 Monate auftraten und unter reduzierter proaktiver Anwendung zweimal wöchentlich erhalten blieben. Die DLQI‐Werte sanken innerhalb der ersten 3 Monate signifikant. Während der Behandlung traten keine neuen Hauttumoren auf. Schlussfolgerungen: SC‐Creme ist eine vielversprechende, zielgerichtete Langzeittherapie für DSAP, die nachhaltige Wirksamkeit, gute Verträglichkeit sowie verbesserte Lebensqualität bietet. Die individuelle Reduktion der Anwendung von täglicher zu proaktiver zweimal wöchentlicher Therapie könnte wesentlich für die Krankheitskontrolle sein und möglicherweise zu einer wichtigen Komponente bei der Prävention von Hauttumoren in dieser speziellen Patientengruppe werden.
- 7 July 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 896-904
Open AccessLanganhaltende Krankheitskontrolle der disseminierten superfiziellen aktinischen Porokeratose (DSAP) mittels topischer Anwendung von 2% Simvastatin/2% Cholesterin‐Creme
Zusammenfassung: Einleitung: Die disseminierte superfizielle aktinische Porokeratose (DSAP) ist eine seltene Keratinisierungsstörung, die mit einem erhöhten Risiko für kutane Tumoren verbunden ist. Zielsetzung: Ziel der Studie war die Entwicklung eines praktikablen und einfach anwendbaren Behandlungsregimes für die langfristige Kontrolle der DSAP einschließlich der Prävention neuer Hauttumoren. Patienten und Methodik: Insgesamt 19 Patienten mit DSAP wurden über einen Zeitraum von maximal 18 Monaten topisch mit einer Creme mit 2% Simvastatin und 2% Cholesterin (SC) behandelt. Der Schweregrad der Erkrankung wurde mittels Investigator Global Assessment (IGA) bewertet, während die Lebensqualität mittels Dermatology Life Quality Index (DLQI) erfasst wurde. Nebenwirkungen sowie die Entwicklung neuer Tumoren wurden dokumentiert. Ergebnisse: In allen behandelten Bereichen zeigte sich eine signifikante Verbesserung der IGA‐Werte (p < 0,001), wobei die meisten Fortschritte innerhalb der ersten 3 Monate auftraten und unter reduzierter proaktiver Anwendung zweimal wöchentlich erhalten blieben. Die DLQI‐Werte sanken innerhalb der ersten 3 Monate signifikant. Während der Behandlung traten keine neuen Hauttumoren auf. Schlussfolgerungen: SC‐Creme ist eine vielversprechende, zielgerichtete Langzeittherapie für DSAP, die nachhaltige Wirksamkeit, gute Verträglichkeit sowie verbesserte Lebensqualität bietet. Die individuelle Reduktion der Anwendung von täglicher zu proaktiver zweimal wöchentlicher Therapie könnte wesentlich für die Krankheitskontrolle sein und möglicherweise zu einer wichtigen Komponente bei der Prävention von Hauttumoren in dieser speziellen Patientengruppe werden.
- Open Access
- 29 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 896-902
Long‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream
Summary: Introduction: Disseminated superficial actinic porokeratosis (DSAP) is a rare keratinization disorder associated with an increased risk of cutaneous tumors. Objectives: To develop a feasible and easy‐to‐apply treatment regimen for long‐time disease control of DSAP including prevention of new skin tumors. Patients and Methods: 19 patients with DSAP were treated with 2% simvastatin/2% cholesterol (SC) cream for a maximum period of 18 months. Disease severity was assessed via Investigator Global Assessment (IGA), and quality of life (QoL) was measured using the Dermatology Life Quality Index (DLQI). Adverse events and tumor development were documented. Results: Significant improvement in IGA scores was observed across all treated regions (p < 0.001), with most progress occurring in the first 3 months but maintained under a reduced proactive application schedule twice weekly. DLQI scores decreased significantly within the first 3 months. No new skin tumors developed during treatment. Conclusions: SC cream is a promising long‐term, targeted treatment for DSAP, offering sustained efficacy, good tolerability, and improved QoL. The individual tapering from daily use to a proactive approach twice a week may be a key factor for disease control and may become an important component of skin tumor prevention in this specific patient population.
- 29 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (7) , 896-902
Open AccessLong‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream
Summary: Introduction: Disseminated superficial actinic porokeratosis (DSAP) is a rare keratinization disorder associated with an increased risk of cutaneous tumors. Objectives: To develop a feasible and easy‐to‐apply treatment regimen for long‐time disease control of DSAP including prevention of new skin tumors. Patients and Methods: 19 patients with DSAP were treated with 2% simvastatin/2% cholesterol (SC) cream for a maximum period of 18 months. Disease severity was assessed via Investigator Global Assessment (IGA), and quality of life (QoL) was measured using the Dermatology Life Quality Index (DLQI). Adverse events and tumor development were documented. Results: Significant improvement in IGA scores was observed across all treated regions (p < 0.001), with most progress occurring in the first 3 months but maintained under a reduced proactive application schedule twice weekly. DLQI scores decreased significantly within the first 3 months. No new skin tumors developed during treatment. Conclusions: SC cream is a promising long‐term, targeted treatment for DSAP, offering sustained efficacy, good tolerability, and improved QoL. The individual tapering from daily use to a proactive approach twice a week may be a key factor for disease control and may become an important component of skin tumor prevention in this specific patient population.
- Open Access
- 30 May 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (12) , 3188-3191.e1
Epidermal IL-36 and CCL17 Protein Expression Distinguish Palmar Eczema from Palmar Psoriasis
- 30 May 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (12) , 3188-3191.e1
Open AccessEpidermal IL-36 and CCL17 Protein Expression Distinguish Palmar Eczema from Palmar Psoriasis
- Open Access
- 19 May 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv42794
Determinants of Quality of Life in Patients with Atopic Dermatitis and Psoriasis: A Multivariate Approach
Health-related quality of life (HRQoL) is reduced in atopic dermatitis and psoriasis. Several factors impact HRQoL including sociodemographic and skin disease-related characteristics, health behaviours, cardiometabolic comorbidities, and psychological conditions. However, their differential and unique effects on HRQoL are not well studied. In this cross-sectional online survey, adult patients with atopic dermatitis (n = 155) or psoriasis (n = 246) provided data on features of their respective skin diseases, health behaviours, and cardiometabolic comorbidities. Validated self-report measures assessed HRQoL, psychopathology (Patient Health Questionnaire-4), and stress (Perceived Stress Scale). Linear regression analyses were used to determine key predictors of HRQoL. In atopic dermatitis, linear regression analyses revealed that self-rated disease severity (Patient-Oriented Eczema Measure), anxiety, and stress were significant predictors of the Dermatology Life Quality Index (DLQI), explaining 59% of the variance. In psoriasis, disease severity (Psoriasis Symptoms and Signs Diary) and depression significantly predicted DLQI, with an explained variance of 57%. Health behaviours and cardiometabolic comorbidities did not impact DLQI scores. While skin disease severity is the most important determinant of HRQoL, stress and anxiety are important in atopic dermatitis, whereas depression is relevant in psoriasis. These findings hold implications for both clinical practice and research.
- 19 May 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv42794
Open AccessDeterminants of Quality of Life in Patients with Atopic Dermatitis and Psoriasis: A Multivariate Approach
Health-related quality of life (HRQoL) is reduced in atopic dermatitis and psoriasis. Several factors impact HRQoL including sociodemographic and skin disease-related characteristics, health behaviours, cardiometabolic comorbidities, and psychological conditions. However, their differential and unique effects on HRQoL are not well studied. In this cross-sectional online survey, adult patients with atopic dermatitis (n = 155) or psoriasis (n = 246) provided data on features of their respective skin diseases, health behaviours, and cardiometabolic comorbidities. Validated self-report measures assessed HRQoL, psychopathology (Patient Health Questionnaire-4), and stress (Perceived Stress Scale). Linear regression analyses were used to determine key predictors of HRQoL. In atopic dermatitis, linear regression analyses revealed that self-rated disease severity (Patient-Oriented Eczema Measure), anxiety, and stress were significant predictors of the Dermatology Life Quality Index (DLQI), explaining 59% of the variance. In psoriasis, disease severity (Psoriasis Symptoms and Signs Diary) and depression significantly predicted DLQI, with an explained variance of 57%. Health behaviours and cardiometabolic comorbidities did not impact DLQI scores. While skin disease severity is the most important determinant of HRQoL, stress and anxiety are important in atopic dermatitis, whereas depression is relevant in psoriasis. These findings hold implications for both clinical practice and research.
- Open Access
- 21 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Facets of shame and their impact on quality of life in patients with atopic dermatitis and psoriasis
Shame is a complex emotion with different facets. Skin shame is a specific aspect of body shame, which involves the skin perceived as inferior or flawed. Its role in atopic dermatitis (AD) and psoriasis is not well investigated. This explorative study pursued three objectives: First, the comparative analysis of shame and its facets in AD and psoriasis. Second, analysis of the association of skin shame with other shame facets, depression, and anxiety. Third, exploration of the unique impact of shame and its different facets on quality of life (QoL) in AD and psoriasis patients. This cross-sectional online survey encompassing German-speaking patients included several self-report measures on skin and general shame, depression, and anxiety as well as the Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), and Psoriasis Symptoms and Signs Diary (PSSD). Data from 413 adult participants with AD (N = 162) or psoriasis (N = 251) were analyzed. There were no significant differences in skin or general shame, depression, or anxiety between those with AD or psoriasis. Skin shame as well as other aspects of shame were associated with younger age, female sex, depression, anxiety, and QoL. Analysis of AD and psoriasis subsamples revealed significant correlations of disease severity with skin shame, depression, anxiety, and DLQI. Hierarchical linear regression analyses indicated that skin shame was the second most important determinant of QoL after self-assessed disease severity. Systematic consideration of shame in AD and psoriasis is necessary in order to effectively reduce disease burden and enhance QoL.
- 21 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessFacets of shame and their impact on quality of life in patients with atopic dermatitis and psoriasis
Shame is a complex emotion with different facets. Skin shame is a specific aspect of body shame, which involves the skin perceived as inferior or flawed. Its role in atopic dermatitis (AD) and psoriasis is not well investigated. This explorative study pursued three objectives: First, the comparative analysis of shame and its facets in AD and psoriasis. Second, analysis of the association of skin shame with other shame facets, depression, and anxiety. Third, exploration of the unique impact of shame and its different facets on quality of life (QoL) in AD and psoriasis patients. This cross-sectional online survey encompassing German-speaking patients included several self-report measures on skin and general shame, depression, and anxiety as well as the Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), and Psoriasis Symptoms and Signs Diary (PSSD). Data from 413 adult participants with AD (N = 162) or psoriasis (N = 251) were analyzed. There were no significant differences in skin or general shame, depression, or anxiety between those with AD or psoriasis. Skin shame as well as other aspects of shame were associated with younger age, female sex, depression, anxiety, and QoL. Analysis of AD and psoriasis subsamples revealed significant correlations of disease severity with skin shame, depression, anxiety, and DLQI. Hierarchical linear regression analyses indicated that skin shame was the second most important determinant of QoL after self-assessed disease severity. Systematic consideration of shame in AD and psoriasis is necessary in order to effectively reduce disease burden and enhance QoL.
- Open Access
- 19 August 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (7) , 1324-1335
Epidermal proteomics demonstrates Elafin as a psoriasis‐specific biomarker and highlights increased anti‐inflammatory activity around psoriatic plaques
Background: Eczema and psoriasis are common diseases. Despite both showing active epidermal contribution to the inflammatory process, their molecular aetiology and pathological mechanisms are different.Objective: Further molecular insight into these differences is therefore needed to enable effective future diagnostic and treatment strategies. The majority of our mechanistic and clinical understanding of psoriasis and eczema is derived from RNA, immunohistology and whole skin biopsy data.Methods: In this study, non‐invasive epidermal sampling of lesional, perilesional and non‐lesional skin from diseased and healthy skin was used to perform an in depth proteomic analysis of epidermal proteins.Results: Our findings confirmed the psoriasis‐associated cytokine IL‐36γ as an excellent protein biomarker for lesional psoriasis. However, ELISA and ROC curve analysis of 53 psoriasis and 42 eczema derived samples showed that the sensitivity and specificity were outperformed by elastase‐specific protease inhibitor, elafin. Of note, elafin was also found upregulated in non‐lesional psoriatic skin at non‐predilection sites demonstrating inherent differences between the non‐involved skin of healthy and psoriatic individuals. Mass spectrometry and ELISA analysis also demonstrated the upregulation of the anti‐inflammatory molecule IL‐37 in psoriatic perilesional but not lesional skin. The high expression of IL‐37 surrounding psoriatic plaque may contribute to the sharp demarcation of inflammatory morphology changes observed in psoriasis. This finding was also specific for psoriasis and not seen in atopic dermatitis or autoimmune blistering perilesional skin. Our results confirm IL‐36γ and add elafin as robust, hallmark molecules distinguishing psoriasis and eczema‐associated inflammation even in patients under systemic treatment.Conclusions: Overall, these findings highlight the potential of epidermal non‐invasive sampling and proteomic analysis to increase our diagnostic and pathophysiologic understanding of skin diseases. Moreover, the identification of molecular differences in healthy‐looking skin between patients and healthy controls highlights potential disease susceptibility markers and proteins involved in the initial stages of disease.
- 19 August 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (7) , 1324-1335
Open AccessEpidermal proteomics demonstrates Elafin as a psoriasis‐specific biomarker and highlights increased anti‐inflammatory activity around psoriatic plaques
Background: Eczema and psoriasis are common diseases. Despite both showing active epidermal contribution to the inflammatory process, their molecular aetiology and pathological mechanisms are different.Objective: Further molecular insight into these differences is therefore needed to enable effective future diagnostic and treatment strategies. The majority of our mechanistic and clinical understanding of psoriasis and eczema is derived from RNA, immunohistology and whole skin biopsy data.Methods: In this study, non‐invasive epidermal sampling of lesional, perilesional and non‐lesional skin from diseased and healthy skin was used to perform an in depth proteomic analysis of epidermal proteins.Results: Our findings confirmed the psoriasis‐associated cytokine IL‐36γ as an excellent protein biomarker for lesional psoriasis. However, ELISA and ROC curve analysis of 53 psoriasis and 42 eczema derived samples showed that the sensitivity and specificity were outperformed by elastase‐specific protease inhibitor, elafin. Of note, elafin was also found upregulated in non‐lesional psoriatic skin at non‐predilection sites demonstrating inherent differences between the non‐involved skin of healthy and psoriatic individuals. Mass spectrometry and ELISA analysis also demonstrated the upregulation of the anti‐inflammatory molecule IL‐37 in psoriatic perilesional but not lesional skin. The high expression of IL‐37 surrounding psoriatic plaque may contribute to the sharp demarcation of inflammatory morphology changes observed in psoriasis. This finding was also specific for psoriasis and not seen in atopic dermatitis or autoimmune blistering perilesional skin. Our results confirm IL‐36γ and add elafin as robust, hallmark molecules distinguishing psoriasis and eczema‐associated inflammation even in patients under systemic treatment.Conclusions: Overall, these findings highlight the potential of epidermal non‐invasive sampling and proteomic analysis to increase our diagnostic and pathophysiologic understanding of skin diseases. Moreover, the identification of molecular differences in healthy‐looking skin between patients and healthy controls highlights potential disease susceptibility markers and proteins involved in the initial stages of disease.
- Open Access
- 8 July 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (7) , 936-946
Real‐World‐Effektivität und Sicherheit der LAight‐Therapie bei Patienten mit Hidradenitis suppurativa
Zusammenfassung: Hintergrund und Ziele: Hidradenitis suppurativa (HS)/Acne inversa (Ai) ist eine chronische, stark beeinträchtigende Erkrankung mit begrenzten Therapiemöglichkeiten. Die gerätebasierte LAight‐Therapie wurde 2017 in Europa zugelassen. Ziel dieser Studie war es, die Auswirkungen einer Real‐World‐Versorgung mit der LAight‐Therapie auf die Krankheitsaktivität und ‐belastung von 3437 Patienten zu analysieren.Patienten und Methodik: In die Analyse wurden alle Patienten aufgenommen, die eine HS‐Diagnose und mindestens eine LAight‐Behandlung erhalten hatten. Die Endpunkte Hidradenitis Suppurativa Severity Score System (IHS4), Schmerz auf der numerischen Ratingskala (pain‐NRS) und der Dermatologische‐Lebensqualitäts‐Index (DLQI) wurden mit Hilfe eines linearen gemischten Modells für wiederholte Messungen (MMRM) über 26 Wochen Versorgung mit der LAight‐Therapie analysiert. Darüber hinaus wurden die Responderraten für alle Endpunkte berechnet und das Sicherheitsprofil der Therapie sowie die Patientenzufriedenheit eingehend untersucht.Ergebnisse: Während der 26‐wöchigen Versorgung mit LAight wurde ein signifikanter Rückgang des IHS4, Schmerz‐NRS und DLQI erreicht. Der BMI hatbei Therapiestart hatte einen signifikant negativen Einfluss auf das Therapieansprechen hinsichtlich Schmerz‐NRS und DLQI.Schlussfolgerungen: Diese Studie bestätigt, dass die LAight‐Therapie zu einer überzeugenden Krankheitskontrolle in allen Schweregraden führt und eine wertvolle Ergänzung des therapeutischen Repertoires bei HS darstellt.
- 8 July 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (7) , 936-946
Open AccessReal‐World‐Effektivität und Sicherheit der LAight‐Therapie bei Patienten mit Hidradenitis suppurativa
Zusammenfassung: Hintergrund und Ziele: Hidradenitis suppurativa (HS)/Acne inversa (Ai) ist eine chronische, stark beeinträchtigende Erkrankung mit begrenzten Therapiemöglichkeiten. Die gerätebasierte LAight‐Therapie wurde 2017 in Europa zugelassen. Ziel dieser Studie war es, die Auswirkungen einer Real‐World‐Versorgung mit der LAight‐Therapie auf die Krankheitsaktivität und ‐belastung von 3437 Patienten zu analysieren.Patienten und Methodik: In die Analyse wurden alle Patienten aufgenommen, die eine HS‐Diagnose und mindestens eine LAight‐Behandlung erhalten hatten. Die Endpunkte Hidradenitis Suppurativa Severity Score System (IHS4), Schmerz auf der numerischen Ratingskala (pain‐NRS) und der Dermatologische‐Lebensqualitäts‐Index (DLQI) wurden mit Hilfe eines linearen gemischten Modells für wiederholte Messungen (MMRM) über 26 Wochen Versorgung mit der LAight‐Therapie analysiert. Darüber hinaus wurden die Responderraten für alle Endpunkte berechnet und das Sicherheitsprofil der Therapie sowie die Patientenzufriedenheit eingehend untersucht.Ergebnisse: Während der 26‐wöchigen Versorgung mit LAight wurde ein signifikanter Rückgang des IHS4, Schmerz‐NRS und DLQI erreicht. Der BMI hatbei Therapiestart hatte einen signifikant negativen Einfluss auf das Therapieansprechen hinsichtlich Schmerz‐NRS und DLQI.Schlussfolgerungen: Diese Studie bestätigt, dass die LAight‐Therapie zu einer überzeugenden Krankheitskontrolle in allen Schweregraden führt und eine wertvolle Ergänzung des therapeutischen Repertoires bei HS darstellt.
- Open Access
- 28 May 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (7) , 936-945
Real‐world effectiveness and safety of the LAight‐therapy in patients with hidradenitis suppurativa
Summary: Background and objectives: Hidradenitis suppurativa (HS)/Acne inversa (Ai) is a chronic debilitating disease with limited therapy options. The device‐based LAight therapy was approved in Europe in 2017. The aim of this study was to evaluate the effect of real‐world care with at least one treatment with LAight therapy on disease activity and burden in 3,437 patients.Patients and Methods: Patients were included in the analysis if they had a diagnosis of HS and received at least one treatment. The endpoints Hidradenitis Suppurativa Severity Score System (IHS4), pain on the numeric rating scale (pain‐NRS) and Dermatology Life Quality Index (DLQI) were analyzed using a linear mixed model for repeated measures (MMRM) over 26 weeks of care with LAight therapy. Furthermore, responder rates were calculated for all endpoints, and the therapy's safety profile and patient satisfaction were thoroughly examined.Results: A significant decrease in IHS4, pain‐NRS, and DLQI was achieved during 26 weeks of care with LAight. The BMI at baseline had a significant negative effect on therapy response for pain‐NRS and DLQI.Conclusions: This study confirms that LAight therapy leads to satisfactory disease control in all stages of severity and is a valuable addition to the therapeutic repertoire of HS.
- 28 May 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (7) , 936-945
Open AccessReal‐world effectiveness and safety of the LAight‐therapy in patients with hidradenitis suppurativa
Summary: Background and objectives: Hidradenitis suppurativa (HS)/Acne inversa (Ai) is a chronic debilitating disease with limited therapy options. The device‐based LAight therapy was approved in Europe in 2017. The aim of this study was to evaluate the effect of real‐world care with at least one treatment with LAight therapy on disease activity and burden in 3,437 patients.Patients and Methods: Patients were included in the analysis if they had a diagnosis of HS and received at least one treatment. The endpoints Hidradenitis Suppurativa Severity Score System (IHS4), pain on the numeric rating scale (pain‐NRS) and Dermatology Life Quality Index (DLQI) were analyzed using a linear mixed model for repeated measures (MMRM) over 26 weeks of care with LAight therapy. Furthermore, responder rates were calculated for all endpoints, and the therapy's safety profile and patient satisfaction were thoroughly examined.Results: A significant decrease in IHS4, pain‐NRS, and DLQI was achieved during 26 weeks of care with LAight. The BMI at baseline had a significant negative effect on therapy response for pain‐NRS and DLQI.Conclusions: This study confirms that LAight therapy leads to satisfactory disease control in all stages of severity and is a valuable addition to the therapeutic repertoire of HS.